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ABSTRACT
The Lyme disease spirochete Borrelia burgdorferi has a very unusual genome
composed of one linear chromosome and up to 21 linear and circular plasmids. Several
plasmids are known to be important either for mammalian infection or tick colonization.
A single spirochete harbors up to 7 different cp32 plasmids; however, nothing is known
about their role in mammalian infection. The plasmids in this family are well maintained
during in vitro cultivation, making it difficult to study their functions. To effectively deplete
the plasmids, an 8kbp fragment containing essential elements for replication and
partitioning in B. burgdorferi was amplified from one of the cp32 plasmids, cp32-3, and
cloned into the vector pGE22 that carries a gentamycin resistance cassette and
essential elements for replication in Escherichia coli.

The resulting construct,

pG22cp32-3plus, was electroporated into borrelial cells. By increasing gentamycin
selection pressure, the spirochetes were forced to lose the corresponding cp32 plasmid.
This strategy can be used to knock out other members of the cp32 family.
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INTRODUCTION
LYME DISEASE
DISCOVERY
Lyme disease was discovered in 1975 in Lyme, Connecticut when children in the
area were being diagnosed with juvenile rheumatoid arthritis at 100% higher than
normal rate. Dr. Allen Steere along with other doctors traced the symptoms to an
unknown bacterial infection transmitted by local deer ticks. In 1977, the newly
characterized disease was named Lyme disease (Steere, et al. 1977).
The Centers for Disease Control and Prevention (CDC) began conducting
national surveillance in 1980 and has continued to compile data since 1982 (Centers for
Disease Control and Prevention, 1982). Lyme disease became the most commonly
reported arthropod-borne disease in the United States between 1984 and 1985 when an
average of 1,500 cases were reported to the CDC (Centers for Disease Control and
Prevention, 1985). Since that time, incidence of the disease has steadily increased to
over 20,000 cases annually (Figure 1).
According to the most recent statistics published by the CDC, there were 23,305
reported cases of Lyme disease in 2005 (Centers for Disease Control and Prevention,
2007). Historically, Lyme disease has been characterized in every state but is most
common in the Northeastern, mid-Atlantic, and North Central states (Figure 2). In the
ten states where Lyme disease is most prevalent, the incidence per 100,000 persons
increases from the national average of 7.9 cases to 31.9 cases (Centers for Disease
Control and Prevention, 2007).
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Figure 1: Reported cases of Lyme Disease 1982-2005 (Centers for Disease Control and
Prevention, 1982; Centers for Disease Control and Prevention, 1985; Centers for Disease
Control and Prevention, 2006; Centers for Disease Control and Prevention, 2001; Centers
for Disease Control and Prevention, 2007). Over the last twenty-four years the CDC has
tracked Lyme disease in the United States. Since reporting began, the CDC has shown
that the number of cases has risen from 491 to 23,305 cases reported in 2005.
LOCATION OF REPORTED CASES OF LYME DISEASE 2005

Figure 2: Location of reported cases of Lyme Disease 2005 (Centers for Disease Control
and Prevention, 2007). In 2005 the CDC compiled the location data for the 23,305 reported
Lyme disease cases in the United States. Higher rates of incidence can be seen in the
TRANSMISSION
Northeastern
to North-Central United States.
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The relative risk of contracting
ontracting Lyme disease is partly due to the distribution of
the disease’s known transmission vectors as well as the presence of the disease
causing bacteria and availability of hosts for tick survival (LoGiudice et al.,
al 2003). The
black-legged tick, Ixodes scapularis
scapularis, previously identified as Ixodes dammini,
dammini also
known as the common deer tick
tick, was originally identified as the key to the bacteria's
spread in the original cases by the doctors investigating the then unknown outbreak of
Lyme disease in rural Connecticut (Steere et al., 1978; Oliver et al., 1993). Ixodes
scapularis is primarily responsible for infection in the Eastern
ern United States where the
majority of infections takes place; however, Ixodes pacificus,, the Western black-legged
black
tick, is responsible
sponsible for infection o
on the West Coast (Figure 3) (Steere et al., 1978;
Burgdorfer, Lane et al.,1985,
1985, LoGiudice et al.,2003).
PRESENCE OF TRANSMIS
TRANSMISSION VECTORS OF LYME DISEASE

Figure 3: Presence of transmission vvectors of Lyme Disease (Centers for Disease
Control and Prevention, 1999).. The above map shows the relative risk of residents to
contract Lyme disease due to the presen
presence of the transmission vector. In the Eastern
United States I. scapularis ticks are responsible for transmitting
g infection while I. pacificus
is the primary vector on the West Coast.
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The ticks known to transmit Lyme disease have a two-year life cycle (Figure 4).
Peak larval activity occurs in the latter summer months when larvae feed on a wide
variety of small mammals, primarily mice and birds. Late the next spring the newly
molted tick exits dormancy and the nymph feeds a second time on small mammals. A
second molt occurs late in the second summer and the adult tick becomes active and
begins to feed again in the fall until temperatures drop below freezing. A tick may pick
up the infection at any feeding during its life cycle and has the ability to transmit the
disease at any stage of growth; larvae, nymph, or adult in any feeding after the tick has
become infected (Klompen, 2004). Mice, specifically the white-footed mouse
Peromyscus leucopus, are the primary natural reservoirs for the bacterial infection
(Levine et al., 1985).
LIFE CYCLE OF LYME DISEASE VECTORS

Figure 4: Life cycle of Lyme Disease vectors (American Lyme Disease Foundation, 2006).
The vector of Lyme disease has a two-year life cycle. The tick can obtain the bacteria at
any feeding and transmit the bacteria to any subsequent host.
4

Lyme disease patients are most likely to become infected in June, July, or
August. This trend is the result of the ticks feeding schedule and the higher prevalence
of human outdoor activity during these months (Centers for Disease Control and
Prevention, 2006).
SYMPTOMS
Lyme disease can produce a wide range of symptoms. The most common sign of
the disease is the presence of the classic indicator rash, erythema migrans, located at
the site of the tick bite (Figure 5) (Steere et al., 1983). According to the CDC’s official
definition, erythema migrans begins as a focal red lesion that expands over several
days to weeks (Centers for Disease Control and Prevention, 1997).

As the lesion

expands, the rash will often resemble a bull’s-eye or target due to partial clearing of the
center of the lesion (Centers for Disease Control and Prevention, 1997). The rash,
present in 80% percent of infected people, can last up to several weeks and may be
accompanied by localized swelling (Steere, 1989; Centers for Disease Control and
Prevention, 1997). Around the time the rash presents, other flu-like symptoms such as
joint pains, chills, fever, and fatigue may also appear (Steere et al., 1983; Centers for
Disease Control and Prevention, 1997).
If the infection is left untreated, the bacteria will continue to spread through the
body within several weeks following initial infection. As dissemination occurs, an
infected person may experience migratory joint pain, severe fatigue, and a stiff or
aching neck. The infected individual may also experience tingling or numbness in the
extremities as well as facial palsy (Steere, 2001; Aguero-Rosenfeld et al., 2005).
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ERYTHEMA MIGRANS RASH

Figure 5: Erythema migrans rash (Siegel et al., 2007). The erythema migrans or bull’s
eye rash is a hallmark sign of the invading bacterium that causes Lyme disease.
More severe symptoms can be seen in the months to years following initial
infection. These symptoms include severe headaches, heart palpitations, and dizziness.
The most prominent late stage infection symptom is the progression of severe swelling
and pain in the joints known as arthritis. At this stage of infection, the central nervous
system may also be affected and cognitive disorders may ensue (Steere, 2001; AgueroRosenfeld et al., 2005).
DIAGNOSIS
In 1996 the CDC published the latest official case definition of Lyme disease in
order to standardize the requirements for reporting a disease case. The presence of the
hallmark erythema migrans rash satisfies the criteria the CDC sets forth for a positive
diagnosis (Centers for Disease Control and Prevention, 1997). However, if the patient
does not exhibit evidence of a tick bite or have any known exposure to ticks within the
previous 30 days, the CDC does recommend a laboratory confirmation as with late
stage diagnoses (Centers for Disease Control and Prevention, 1997). Early diagnosis
6

and subsequent treatment can prevent further complications and the advancement of
the disease (Centers for Disease Control and Prevention, 2005).
If early symptoms went undetected, the CDC criteria for a positive diagnosis
requires the presence of at least one late stage infection symptom that is confirmed via
laboratory diagnostic testing (Centers for Disease Control and Prevention, 1997).
Confirmation of the presence of the bacteria can be obtained via the culture of the
bacteria from a clinical specimen removed from the patient (Aguero-Rosenfeld et al.,
2005). Diagnostic confirmation may also be obtained with a CDC recommended twostep blood test for the disease causing bacteria (Centers for Disease Control and
Prevention, 1997).
First the blood should be tested using an enzyme immunoassay, such as
enzyme-linked immunosorbent assay (ELISA) or immunofluorescent assay (IFA), to
detect bacterial antibodies present in the patient specimen (Centers for Disease Control
and Prevention, 1997). Kits approved by the FDA test for either IgG or IgM antibodies to
the bacteria; however, more sensitive test kits screen for both types of antibodies
(Aguero-Rosenfeld et al., 2005). Because these tests provide a high rate of falsepositive results, if a positive result is obtained a second, more specfic test must also be
performed (Centers for Disease Control and Prevention, 1997). A FDA approved
standardized western immunoblot kit should also be used to detect antibodies to
proteins of various sizes produced by the bacteria (Centers for Disease Control and
Prevention, 1997; Aguero-Rosenfeld et al., 2005). Positive results on both tests satisfy
the CDC criteria for a confirmed disease case. In some chronic cases doctors may
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choose to use FDA approved Polymerase Chain Reaction (PCR) kits to test fluid drawn
from a joint or spinal tap to detect bacterial DNA (Aguero-Rosenfeld et al., 2005).
TREATMENT
The Infectious Diseases Society of America (IDSA) has recently updated the
clinical practice guidelines for the treatment of Lyme disease. According to the IDSA’s
2006 guidelines, treatment of the infection with a 14 day course of oral antibiotics such
as doxycycline, amoxicillin, or cefuroxime axetil usually clears the infection and can
prevent further complications caused by the dissemination of the bacteria (Wormser et
al., 2006). Of the three recommended treatments, doxycycline should not be used for
children under 8 or for pregnant or lactating females (Wormser et al., 2006).
The ISDA recommends a 28 day course of oral antibiotics for patients with
persistent symptoms after a first course of oral antibiotics and for patients with the later
stages of disease (Wormser et al., 2006). The longer course of treatment should
significantly improve arthritis and other symptoms of the disease (Wormser et al., 2006).
Patients that exhibit the neurologic components of the disease should be administered
intravenous β-lactam antibiotics such as ceftriaxone, cefotaxime, or penicillin G
(Wormser et al., 2006). Although full resolution of the disease can be obtained, the
chance of the treatment providing a cure decreases with disease progression (Centers
for Disease Control and Prevention, 2006; Wormser et al., 2006).
BORRELIA BURGDORFERI
DISCOVERY
In the fall of 1981, Dr. Jorge Benach collected nymphal I. scapularis ticks from
Shelter Island, New York (Burgdorfer et al., 1982; Oliver et al., 1993). The ticks were
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sent to Dr. William Burgdorfer, a researcher at the NIH Rocky Mountain Laboratories,
where they were analyzed (Burgdorfer et al., 1982). During his analysis an unidentified
spirochetal bacterium was isolated from the tick midgut (Burgdorfer et al., 1982). In
1982 the spirochete was established as the etiologic agent of Lyme disease (Burgdorfer
et al., 1982). The spirochete was later named Borrelia burgdorferi after its discoverer
(Johnson et al., 1984).
Since discovery, at least three genospecies of B. burgdorferi have been found to
cause Lyme disease in humans. In the United States B. burgdorferi sensu stricto is the
only strain of the bacteria that causes Lyme disease (Steere et al., 2004). Two distinctly
different genospecies of the bacteria, Borrelia garinii and Borrelia afzelii, cause infection
in Asia (Baranton et al., 1992; Canica et al., 1993). In Europe, all three genospecies are
present and cause disease (Baranton et al., 1992; Canica et al., 1993).
CHARACTERISTICS AND STRUCTURE
Borrelial cells average 0.2 to 0.5 µm in diameter and 4 to 18 µm in length
(Barbour and Hayes, 1986; Baron, 1996). It is the spirochete’s flagella that are
responsible for the motility and corkscrew, helical cell shape (Figure 6). The 7-20
periplasmic flagella, or axial filaments, originating from the ends of the spirochete are
anchored into the cytoplasmic membrane. These endoflagella wind lengthwise between
the outer membrane and cell wall around the protoplasmic cylinder (Charon and
Goldstein, 2002).
Borreliae are microaerophilic organisms that require oxygen at lower than
normal, 21%, oxygen to survive (Baron, 1996). The bacterium is an obligate parasite, as
it relies on its host’s metabolism. B. burgdorferi does not synthesize its own essential
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nutrients and must obtain amino acids, fatty acids, and other essential elements from its
host (Todder, 2005). In addition, unlike many pathogenic organisms, Borrelia does not
require iron for infection or cellular survival (Posey and Gherardini, 2000).
INTERNAL FLAGELLA

Figure 6: Internal Flagella (Charon and Goldstein 2002). The spirochete is given its
unique helical shape by the internal flagella that are anchored in cytoplasmic membrane
at the ends of the bacteria. The flagella wind lengthwise around the protoplasmic
cylinder. Although the bacteria have many flagella, the graphic depiction is simplified
with a single flagellum.
For laboratory culture, Borrelia is grown in a nutrient rich tissue culture medium
such as variations of Barbour-Stoner-Kelly (BSK) culture medium (Wang et al., 2004).
Since 1993, a modified version of BSK called BSK-Harvard (BSK-H), supplemented
with mammalian serum is the standard medium used (Pollack et al., 1993). During its
life cycle, the bacteria must adapt to survive changing environments that are
encountered in the transition from the cold-blooded tick to a warm-blooded mammal.
Mammalian conditions are mimicked by culturing B. burgdorferi at 35oC/pH 7.0 whereas
the tick environment is approximated by growth at 23oC/pH 8.0 (Stevenson et al., 1995;
Stewart et al., 2005). Although the media can be manipulated to mimic the host or the
vector, experiments performed in vitro can not always be extrapolated to B. burgdorferi
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during the infectious cycle because the bacteria can display different behavior inside
vector or vertebrate host (Singh and Girschick, 2004).
HOST – ORGANISM INTERACTION
The spirochete presents outer surface protein A (OspA) on its surface while it
survives inside the resting, non-feeding tick. The protein serves as an anchor for the
spirochete to the tick midgut. During the bloodmeal, the bacteria migrate out of the tick
midgut into the salivary glands. The bacteria travels along with the saliva excreted into
the animal during tick feeding where it moves through the opening in the skin created by
the tick. In order to establish mammalian infection, Borrelia downregulates the
expression of OspA and upregulates expression of OspC when feeding begins
(Figure7) (Schwan et al., 1995).
After transmission, B. burgdorferi migrates through the extracellular matrix of
host tissue by binding to epithelial cells, neural elements, platelets and red blood cells.
To disseminate, the bacterium uses special binding or adhesion proteins to bind to
OUTER SURFACE PROTEIN EXPRESSION FROM TICK TO MAMMALIAN HOST

Figure 7: Outer Surface Protein Expression from Tick to Mammalian Host (Singh and
Girschick, 2004). The bacterium differentially regulates the expression of OspA and
OspC depending upon its location in order to effectively establish infection. The figure
has been modified from the original version.
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select host proteins such as integrins, proteoglycans and glycoproteins located on the
surface of host cells and in tissue matrixes (Guo et al., 1995; Steere et al., 2004,).
IMMUNOLOGY
It is at the site of the tick bite where the bacterium is presented with the
vertebrate host’s first line of defense, complement-mediated lysis (Steere et al., 2004).
The process of complement activation and subsequent cell lysis as well as borrelial
lipoproteins and cell signals recruit more immune cells to the site of infection (Abbas
and Lichtman, 2005). Initially primary lymphocytes, macrophages, and plasma cells are
localized to the infection site around the erythema migrans rash (Mullegger et al., 2000).
Macrophages stimulated by the bacteria will begin to engulf and kill the bacteria (Abbas
and Lichtman, 2005). The activated macrophages stimulate the maturation of helper T
cells and production of proinflammatory cytokines, particularly interferon-γ (IFNγ),
interleukin-10 (IL-10), tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), and
interleukin-6 (IL-6) (Mullegger et al., 2000; Abbas and Lichtman, 2005).
At the same time, borrelial lipoproteins act as B cell mitogens that independently
stimulate a B cell response to produce antibodies (Steere et al., 2004; Abbas and
Lichtman, 2005). Additionally, T cell mediated responses to nonlipidated proteins use
Th1 cells to prime B cell responses (Steere et al., 2004; Abbas and Lichtman, 2005).
The antibodies produced by the host immune system begin killing spirochetal cells via
complement fixation and opsonization (Steere et al.,2004).
Although an active immune response is present, the borrelial cells survive by
minimizing or changing expression of surface proteins or inhibiting certain responses
(Steere et al., 2004). In order to escape selective immunological pressure caused by the
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host, the bacterial cells can downregulate lipoproteins like OspC (Liang et al., 2002).
The variation of protein expression renders the OspC antibody useless as the antibody
selects for cells with OspC-negative phenotypes or actually induces the protein’s
downregulation (Liang et al., 2002). The bacterial cell also evades the host immune
system by varying the antigenic portions of a expressed protein, namely, the vmp-like
sequence protein E (VlsE) (Zhang et al., 1997). The variation of the VlsE protein is
essential to the survival of the bacteria because the antibody will not recognize the
protein variant (Zhang et al., 1997).

COMPLEMENT REGULATOR-ACQUIRING SURFACE PROTEINS

Figure 8: Complement Regulator-Acquiring Surface Proteins (Singh and Girschick,
2004). Inside the mammalian host the bacterial cells express Erp and CRASP proteins
on its surface. These proteins confer alternative pathway complement resistance by
binding Factor H and FHL-1 proteins. The figure has been modified from the original
version.
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Complement activation via the classic or alternative pathways destroys
pathogens by coating them with opsonising molecules to form the complement
membrane attack complex after entry in the human host; formation of the complex
usually leads to cell lysis (Abbas and Lichtman, 2005). In this instance, Borrelia has
evolved to provide an effective method of avoiding some complement mediated killing
(Singh and Girschick, 2004). B. burgdorferi can express five distinct complement
regulator-acquiring surface proteins (CRASPs) and several OspE/F related proteins,
Erps, on their surfaces that bind the host complement regulators of the alternative
pathway. CRASPs bind Factor H and Factor H-like Protein 1 (FHL-1) which inactivate
C3b and protect the cell from complement mediated killing (Figure 8) (Stevenson and
Akins, 2000; Kraiczy et al., 2001; Kraiczy et al., 2004).
The host’s innate and adaptive responses must work together to control
disseminating bacteria (Steere et al., 2004). While in the later stages of infection the
infected host has high antibody responses towards several borrelial proteins, the host
may still be unable to clear infection. The host’s hyperimmunization is caused by waves
of bacterial growth following antigenic shifting (Akin et al., 1999).
GENETICS
The genome of B. burgdorferi cells consits of about 1,521,419 base pairs (bp) of
nucleic acid. This information is contained on one linear chromosome and up to 21
linear and circular plasmids, the largest plasmid complement of any bacteria (Figure 9)
(Casjens et al., 2000). The single linear chromosome is approximately 910 kilobase
pairs (kbp) in length and contains 853 predicted genes that provide mainly
housekeeping functions for the cell (Baril, et al. 1989, Ferdows and Barbour 1989,
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Fraser, et al. 1997). A significant amount of the bacterium’s genetic material is held in
the extrachromosomal plasmids (Casjens, Palmer et al., 2000; Fraser et al., 1997). In
total, the cell holds 40% of its genetic information in the extrachromosomal DNA;
361,364 bp in 12 distinct linear plasmids as well as 249,330 bp in nine circular plasmids
(Casjens et al., 2000).
The genetic information contained in the cell is highly redundant and dispersed
throughout the chromosome and plasmids (Zuckert and Meyer, 1996; Fraser et al.,
1997; Casjens et al., 1997). The complete genome contains 161 families of paralogous
genes that are similar in function. Members of these gene families can be found on both
the chromosome and on extrachromosomal plasmids. The paralogous gene families
range in size from 2 to 41 members (Casjens, et al., 2000).
DIVERSITY OF GENETIC COMPOSITION

Figure 9: Diversity of Genetic Composition (Stewart et al., 2005). Borrelia is a unique
bacterium that contains one linear chromosome and up to 21 extrachromosomal
elements. The figure has been modified from the original version.
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Borrelia extrachromosomal plasmids can coexist in an individual bacterium
(Hinnebusch and Barbour, 1992). However, Borrelia strains have often been found to
lose one or more plasmids during laboratory propagation and cloning procedures
(Schwan et al., 1988). Among the plasmid-encoded products that have characterized or
proposed functions are proteins required for nutrient acquisition, metabolism, and outer
surface proteins (Fraser et al., 1997; Casjens et al., 2000).
LINEAR PLASMIDS
B. burgdorferi strains have been known to spontaneously lose lp28-1. Bacterial
cells that lose lp28-1 are capable of infecting mice; however, the infection does not
persist (Purser and Norris, 2000; Labandeira-Rey and Skare, 2001). The lack of a
persistent infection may be due to the loss of the vlsE coding region of the plasmid. The
region is comprised of a set of 15 silent cassettes that switch into an expression locus to
give the bacteria antigenic variation of the surface exposed protein (Zhang et al., 1997).
Similarly to lp28-1, borrelia cells can spontaneously loose lp25. This plasmid is
essential for survival in both tick and mammalian hosts, however; lp25 is not required
for in vitro growth (Purser and Norris, 2000). The plasmid harbors bbe22, the gene that
encodes a nicotinamidase. Nicotinamidase is absolutely essential in that it provides the
critical step in converting nicotinamide to nicotinic acid in the exogenous pathway to
synthesizing NAD as an energy source (Purser et al., 2003).
Linear plasmid lp54 also contains many loci hypothesized to be required for
survival in the mammalian host and the tick vector. Lp54 contains the highest
percentage of temperature-regulated gene products, including OspA, OspB and the
decorin binding proteins A and B (DbpA and DbpB) (Ojaimi et al., 2003; Fischer et al.,
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2003). Disruption of the ospA/B operon is linked to reduced tick colonization(Yang et al.,
2004). DbpA and DbpB mediate attachment to host tissue, which aids in initial
colonization and dissemination of the bacteria (Guo et al., 1995; Fischer et al., 2003).
CRASP-1, a factor H-binding protein of B. burgdorferi that is presumably needed to aid
the cell in avoiding complement-mediated killing, is also encoded on lp54 (Kraiczy et al.,
2004).
Unlike lp28-1,lp25, and lp54, linear plasmids lp21, lp28-2, lp28-4, and lp56 do not
appear to be required for mammalian infection or growth in vitro (Purser and Norris,
2000). It is speculated that the genes carried on the plasmids provide different
capacities of selective advantages. The plasmids’ genes may aid the borrelial cells by in
adapting to different hosts and establishing a lasting infection (Purser and Norris, 2000).
CIRCULAR PLASMIDS
The unique circular plasmid cp26 has been shown to be essential and present in
all natural isolates of the bacteria (Byram et al., 2004). Housekeeping genes and
virulence factors are found to be encoded on the plasmid. The very important OspC
protein is encoded by a gene located on cp26 (Grimm et al., 2004; Pal et al.,2004). The
plasmid also encodes a telomere resolvase (resT), which is required to resolve circular
dimers of linear plasmids after replication (Kobryn and Chaconas, 2002).
32 KILOBASE CIRCULAR PLASMIDS
The 32 kilobase circular plasmid family contains almost 20% of the genetic
information of Borrelia. These nine plasmids are each about 30,000 bp in length
(Casjens et al., 2000). Although the plasmids have relatively the same amount of coding
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DNA, the plasmids encode for 33 to 44 functional genes and between 0 to 9
pseudogenes (Table 1) (Casjens et al., 1997; Casjens et al., 2000; Eggers et al., 2002).
32 KILOBASE CIRCULAR PLASMIDS COMPOSITION
Table 1: 32 Kilobase Circular Plasmids Composition (Casjens et al., 2000). The cp32
family of plasmids are highly similar in composition as they are derivatives of each
other. The plasmids are roughly the same size and contain similar numbers of genes.
Table was adapted from original version for conciseness. The figure has been modified
from the original version.
Plasmid

Size

Coding %

Genes

Pseudogenes

cp32-1
cp32-3
cp32-4
cp32-6
cp32-7
cp32-8
cp32-9

30750
30223
30229
29838
30800
30885
30651

92
92
92
92
93
92
92

42
44
39
41
42
43
33

0
0
4
0
0
0
9

No borrelial isolate has ever lost all members of the cp32 family (Casjens et al.,
1997; Purser and Norris, 2000). This important fact suggests that they are essential to
B. burgdorferi, as they may provide critical virulence genes, aid in the bacterium’s
survival, or increase the range of possible hosts. The cp32 family contains at least nine
unique members that are about 80% homologous throughout their sequences (Casjens
et al., 2000). Despite this homology, the cp32 plasmids can all stably coexist within the
same cell (Casjens et al., 1997, Casjens et al., 2000).
The explanation for the ability of such similar plasmids to replicate, segregate,
and coexist in the same cell is found in the plasmids’ first of three hypervariable regions
(Stevenson and Akins, 2000). The first region contains the paralogous gene families,
PF57, PF50, PF32, and PF49 that are responsible for the cp32 family’s replication and
segregation into daughter cells (Figure 10) (Casjens et al., 2000; Eggers et al., 2002;
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Stevenson and Akins, 2000). The region responsible for the plasmids replication is
PF57, as well as the intergenic sequence immediately upstream. The intergenic
sequence is theorized to contain approximately six DnaA boxes, the sites at which
dnaA, a DNA replication initiation protein, bind. The PF57 gene serves as the plasmids
origin of replication. Based on sequence and location, PF32 and PF49 are proposed
partitioning proteins, ParA and ParB, respectively. The ParA and ParB proteins ensure
that the plasmid segregates into each daughter cell (Casjens et al., 2000; Eggers et al.,
2002). Through deletion experiments, PF50 is also deemed essential for as of yet
undetermined reasons (Eggers et al., 2002). It is the higher variability among these
genes, as much as 69% compared to the plasmids’ overall 20% variability, that ensures
all the cp32 plasmids are compatible and can coexist within the same cell (Casjens et
al., 2000; Eggers et al., 2002,).
B. burgdorferi has two other variable regions of DNA on their cp32 plasmids. The
REPLICATION, MAINTENANCE, AND SEGREGATION HYPERVARIABLE REGION

Figure 10: Replication, Maintenance, and Segregation Hypervariable Region (Casjens
et al., 2000). The region found in every cp32 plasmids is responsible for the family’s
replication, maintenance, and segregation. The four genes in the region, PF32, PF49,
PF50, and PF57, and the intergenic sequence upstream of PF57 are clustered together
in each of the cp32s. The figure has been modified from the original version.
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second region contains the erp locus. The Erp proteins OspE and OspF are surface
exposed lipoproteins that are upregulated in the bacteria once the spirochete has
entered the mammalian host (Stevenson et al., 1995). Later experiments have linked
several of these proteins to complement evasion mediated by binding Factor H and
FHL-1 proteins (Kraiczy et al., 2001; Stevenson et al., 2002; Kraiczy et al., 2004).
The final hypervariable region has been named the 2.9 locus (Porcella et al.,
1996). This region contains genes from the multicopy lipoprotein (mlp) paralogous gene
family. The mlp genes encode for a borrelial surfaced exposed protein to which infected
hosts will develop antibodies (Yang et al., 1999). It is hypothesized that this protein
product may assist in interacting with host tissues (Theisen, 1996; Yang et al., 1999).
Most 2.9 loci also contains a gene from the Borrelia direct repeat (bdr) gene family that
possibly play a role in cell regulation, sensing, or signaling (Zückert et al., 1999; Roberts
et al., 2000; Stevenson and Akins, 2000). The two cp32 plasmids, cp32-1 and cp32-6,
that do not contain a bdr contain a rev gene, a gene is a reverse orientation, that is
surface expressed and can act as an antigen while giving the bacteria survival
advantages in diverse environments (Gilmore and Mbow, 1998; Stevenson and Akins,
2000).
Other than these three hypervariable regions, the cp32 plasmids are between 9980% similar (Stevenson and Akins, 2000; Casjens et al., 2000). These nearly
indistinguishable regions of DNA have not been extensively studied; therefore, little is
known about the regions and their potential protein products. Some of these proteins
are speculated to be additional surface expressed lipoproteins as well as secreted
proteins (Stevenson and Akins, 2000).
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Some of the known genes outside of the hypervariable region encode for borrelia
haemolysin proteins A and B (BlyA and BlyB) (Stevenson and Akins, 2000). The two
open reading frames upstream of the 2.9 locus work together to create pore-forming
toxins (Guina and Oliver, 1997). Further experiments have determined that these genes
are actually involved in cell lysis for the release of B. burgdorferi bacteriophage particles
(Eggers and Samuels, 1999). Borrelia uses the bacteriophage ФBB-1 as a natural
means of laterally transferring genetic material to other cells by packaging the genetic
information from the members of the cp32 family and transducing them into other cells
(Figure 11) (Eggers et al., 2001).
PHIBB-1 BACTERIOPHAGE

Figure 11: PhiBB-1 Bacteriophage (Eggers et al., 2001). Borrelia can laterally transfer
genetic information by utilizing the bacteriophage particle ΦBB-1.
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RESEARCH GOALS
Many experiments have been conducted to determine the function of the different
genes on the plasmids of B. burgdorferi. If the genes on a plasmid encode for essential
proteins, the plasmids on which the gene is located must be faithfully maintained by
Borrelia (Purser and Norris, 2000). The required plasmids of Borrelia, lp28-1, lp25, lp54,
and cp26, have genes that encode for proteins that confer infectivity and persistence of
the bacteria (Zhang et al., 1997; Labandeira-Rey and Skare, 2001; Purser et al., 2003;
Ojaimi et al., 2003; Fischer et al., 2003; Kraiczy et al., 2004; Byram et al., 2004).
The cp32 family of plasmids are well maintained inside the B. burgdorferi cell.
Recent studies have characterized many natural isolates of the bacteria obtained from
several sources; no isolate of Borrelia has ever been found to exist with all of the cp32
plasmids missing (Purser and Norris, 2000). When these isolates were examined,
plasmids cp32-1, cp32-2, cp32-7, cp32-4, cp32-6, cp32-8, cp32-9 were almost always
present, suggesting that at least some of the cp32 plasmids provide genetic information
that is necessary for spirochetal survival in nature (Casjens et al., 1997; Purser and
Norris, 2000).
Little is known about the true function of the majority of the cp32 plasmids’
genes, which comprise almost 20% of the borrelial genome (Casjens et al., 2000).
Experiments to determine their function must be performed. To get a broad
understanding of their purpose, plasmid knockout mutants of B. burgdorferi can be
produced. These knockout mutants will provide information on the cp32 plasmids role in
infectivity and pathogenesis and determine if they are required by the bacterium.
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MATERIALS AND METHODS
REAGENTS
LOADING DYE
24.0 mL

Glycerol (EMD Chemicals, Incorporated, Gibbstown, NJ)

4.8 mL

Ethylenediamine Tetraacetic acid (EDTA) (Amresco, Solon, OH)

0.036 g

Xylene Cyanol (Amresco)

11.2 mL

ddH2O

Stored at Room Temperature
50X TRIS-ACETATE-EDTA (TAE) BUFFER
242 g

Tris Base (Amresco)

57.1 mL

Glacial Acetic Acid (Mallinckrodt Baker, Incorporated, Phillipsburg, NJ)

100 mL

0.5 M EDTA (pH8.0) (Amersco)

Dissolved to 1 L with ddH2O
Stored at Room Temperature
1X TAE BUFFER
10 mL

50xTAE

900 mL

ddH2O

Stored at Room Temperature
ELECTOPORATION SOLUTION (EPS) BUFFER
46.5 g

Sucrose (Fisher Scientific Company, Pittsburgh, PA)

75 mL

100% Glycerol (EMD Chemicals, Incorporated)

Dissolved to 500 mL with ddH2O
Adjusted to pH to 7.3 and filtered
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Stored at 4oC
0.8% ETHIDIUM BROMIDE INCORPORATED AGAROSE GEL
0.26 g

UltraPureTM Agarose (Sigma-Aldrich Corporation, St. Louis, MO)

30.0 mL

1x TAE

3 µL

Ethidium Bromide (Sigma-Aldrich Corporation)

1.0% ETHIDIUM BROMIDE INCORPORATED AGAROSE GEL
0.30 g

UltraPureTM Agarose (Sigma-Aldrich Corporation)

30.0 mL

1x TAE

3 µL

Ethidium Bromide (Sigma-Aldrich Corporation)

LURIA-BERTANI (LB) BROTH
10 g

Tryptone (Acros Organics, Geel, Belgium)

10 g

Sodium Chloride (Fisher Scientific Company)

5g

Yeast Extract (Becton, Dickinson and Company, Sparks, MD)

Dissolved to 2000 mL with ddH2O
Adjusted to pH to 8.0
Stored at Room Temperature
*Containing ampicillin (Fisher Scientific Company) at 100 µg/mL (LB-amp)
Stored at 4oC
*Containing gentamycin (Invitrogen Corporation, Carlsbad, CA ) at 5 µg/mL (LB-gent)
Stored at 4oC

LURIA-BERTANI (LB) PLATE
10 g

Tryptone (Acros Organics)

10 g

Sodium Chloride (Fisher Scientific Company)

5g

Yeast Extract (Becton, Dickinson and Company)
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Dissolved to 2000 mL with ddH2O
Adjusted to pH to 8.0
32 g

BatoAgar (Becton, Dickinson and Company)

Autoclaved in 500 mL increments
Stored at 4oC
*Containing ampicillin (Fisher Scientific Company) at 100 µg/mL (LB-amp)
*Containing gentamycin (Invitrogen Corperation) at 5 µg/mL (LB-gent)
BACTERIAL STRAINS AND PLASMIDS
Borrelia burgdorferi strain 5A4 and 13A (Table 2) were cultured from the
laboratory stock in BSK-H complete media (Sigma-Aldrich Corporation) supplemented
with 6% rabbit serum (Sigma-Aldrich Corporation) and incubated inside a Forma Series
II water jacketed CO2 Incubator (Thermo Electron Corporation) at 33oC and 5% CO2.
The cells were grown to an approximate density of 100 spirochetes per field of view for
further use or flash frozen in liquid nitrogen and stored at -80ºC until needed.
DH5α chemically competent Escherichia coli cells (Invitrogen Corporation) were
transformed using the E. coli cell transformation procedure (Table 2). During the course
of the study several constructed plasmids were introduced into the cells for amplification
for further use in the study (Table 2).
GENOMIC DNA PREPARATION
Genomic DNA was isolated from B. burgdorferi 5A4 and used for Polymerase
Chain Reaction (PCR) amplification procedures. Cells were harvested in 1 mL volumes
by centrifugation at 16,100 x g for 12 minutes at 4oC in an Eppendorf 5415R Table Top
Micro-Centrifuge (Eppendorf Scientific, Incorporated, Madison, WI). The DNA from
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BACTERIAL STRAINS AND PLASMIDS USED IN STUDY
Table 2: Bacterial strains and plasmids used in study. The bacterial strains and plasmids
listed above were used to perform the outlined experiments.
Strain or Plasmid

Description

Source

Borrelia burgdorferi
5A4

B. burgdorferi high-infectivity, low passage,
strain B31 with all plasmids present

Steven Norris
(Purser and Norris,
2000)

13A

B. burgdorferi highly transformable, lowinfectivity, high passage strain 5A13
(Purser and Norris, 2000) lacking plasmids
lp25- lp56-

Liang Lab

pG22cp32-3plus

B. burgdorferi strain 5A13 with pG22cp323plus plasmid

This Study

F-, φ80dlacZ∆M15, ∆(lacZYA-argF)U169,
deoR, recA1, endA1, hsdR17(rk-, mk+),
phoA, supE44, λ-, thi-1, gyrA96, relA1

Invitrogen
Corporation

Escherichia coli
DH5α
Plasmids
Liang Lab
(Downie et al.,
2004)

pNCO1T

TA cloning vector

pNCO1Tcp32-3

pNCO1T with cp32-3 putative maintenance
region obtained from B. burgdorferi 5A4
inserted into multiple cloning region at NcoI
site

This Study

pBSVGE22

pBSV2G cloning vector inserted with
borrelial bbe22 gene

Liang Lab

pG22

pBSVGE22 shortened with GenF/GenR
primers

This Study

pG22cp32-3plus

pG22 inserted with cp32-3plus region
obtained from pNCO1Tcp32-3

This Study
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pelletted cells was extracted using the Sigma GenElute™ Mammalian Genomic DNA
Miniprep Kit (Sigma-Aldrich Corporation).
The pellet of cells was resuspended in 200 µL Resuspension Buffer (SigmaAldrich Corporation) and 20 µL of Proteinase K (Sigma-Aldrich Corporation) was added.
The mixture was incubated in a 50oC water bath for 1 hour. After incubation, 200 µL of
Lysis Solution (Sigma-Aldrich Corporation) was added to the centrifuge tube and mixed
via inversion. The tube was then incubated for 10 minutes at 70oC.
A Nucleic Acid Binding Column (Sigma-Aldrich Corporation) was prepared by
adding 500 µL of Column Preparing Solution (Sigma-Aldrich Corporation) to the column
and spun at 3,900 x g for 1 minute. The collection tube was discarded. Ethanol at a
volume of 200 µL was added to the lysed cell suspension. The tube was then vortexed
and the contents added to the prepared binding column with new collection tube
attached. The apparatus was spun at 3,900 x g for 1 minute.
The collection tube was replaced again and the bound DNA was washed by with
500 µL Wash Solution (Sigma-Aldrich Corporation) with ethanol and spun again for 1
minute at 3,900 x g. The wash was repeated and the apparatus was spun at 16,100 x g
for 3 minutes to allow the DNA to dry onto the column.
Once the final collection tube was added to the column, the DNA was eluted by
adding 200 µL sterile autoclaved ddH2O and spinning the apparatus at 3,900 x g for 1.5
minutes. The resulting collection of DNA in ddH2O was either used immediately or
stored for later use at -20oC.
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PRIMER DESIGN
Primers for this experiment were designed using Clone Manager Suite version
7.1 (Scientific and Educational Software, Cary, NC). Sequences used in the design
process were obtained via the Entrez Nucleotide database (Table 3). All primers were
synthesized by Integrated DNA Technologies, Incorporated (Coralville, IA) (Table 4).
The primers were used at a working concentration of 12 pM.
GENETIC SEQUENCE ACCESS NUMBERS
Table 3: Genetic Sequence Access Numbers. cp32 genetic sequences were accessed
via the Entrez Nucleotide database. Accession numbers for each cp32 are listed
above.

Primers to amplify the putative maintenance required for autonomous replication
and segregation region of cp32-3 were designed to include PF57, PF50, PF32, and
PF49 genes along with 5.5 kbp of DNA flanking the region.

Although the regions

surrounding this area are highly homologous between cp32 plasmids, the extra DNA
was included in the amplification to ensure amplification of only the single cp32-3. The
forward primer cp32-3F1NcoI was used in combination with either reverse primer
cp32F1Nco1 or cp32R2 at an annealing temperature of 60oC in amplification PCR
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procedures. The amplification produced the approximately 8.4 kbp fragment of DNA
used in the experiments. All three primers introduced an NcoI restriction site onto the
ends of the DNA.
Primers to confirm the presence of the 8.4 kbp region of cp32-3 DNA were
developed to amplify the 500 bp region of DNA located toward the end of the PF161
gene extending toward PF57. The concp32F and concp32R primers used in
confirmation PCR procedures were annealed to denatured DNA at 60oC.
Primers to amplify and shorten the pBSVGE22 plasmid were designed to amplify
only the necessary components of the plasmid. For amplification purposes the Gen32F
and Gen32R plasmids were used in combination at an annealing temperature of 60oC.
The approximately 2.8 kbp product with newly introduced NcoI sites was used in the
construction of the pG22cp32-3plus plasmid.
To confirm the presence of the gentamycin acetyltransferase gene, primers were
developed to amplify a 519 bp portion of the gene. The GenF and GenR primers were
used in PCR confirmation procedures with annealing temperatures of 50oC.
PRIMERS USED IN STUDY
Table 4: Primers used in study. The primers above were used throughout the various
procedures described. The primers were synthesized by Integrated DNA
Technologies, Incorporated.
POLYMERASE CHAIN REACTION
Primer Name
Sequence (5’ to 3’)
cp32-3F1Nco1
ATCCATGGGTTTTGGAGTTATTGTAGT
Amplification Polymerase Chain
Reactions (PCR) were performed with a PCR
cp32R1Nco1
AACCATGGCTAGCTGCATTTGTGCTTGTA
reaction cp32R2
mixture that included approximately
1 pg - 10 ng DNA template, 10uL 5x
GACCATGGTACTCAGCAATAGCACTACT
concp32F
CCAGTACTTGTACTGTAGAATGTA
High-Fidelity
Buffer
(Finnzymes,
Espoo,
Finland) with 1.5 mM MgCl2, 10 mM dNTP (200
concp32R
TAGGCTATACTACAAACAGTGTAG
Gen32F
AACCATGGAATAAGCAGTCAAGTCTAGTCT
µM eachGen32R
dNTP) (Takara Bio Incorporated,
Shiga, Japan), 0.02 U/µL (0.5 µL) phusion
AACCATGGAAACCCTAAGGATGAACTT
GenF
TCACGGTGTTATGGAAATAG
Taq polymerase
(Finnzymes),
and
0.5
µM
reaction specific primers (Integrated DNA
GenR
GACTGCGAGATCATAGATATAG
BBS41F
CTGTTTAATCCACCACCAGTA
BBS41R
GGAGAAAGTACTGAGAAAGT
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Technologies) made to 50 µL volume with sterile autoclaved ddH2O. The PCR reaction
mixture was subjected to the following conditions inside the MyCycler Thermal Cycler
(Bio-Rad Laboratories, Incorporated, Hercules, CA). The DNA was initially denatured at
98ºC for 6 seconds. Next, the reaction mixture was subjected to 35 cycles of
amplification during which the DNA was denatured at 98ºC for 6 seconds, primers were
annealed at Tm+3oC for 23 seconds, and the primer was extended at 72ºC for 30
seconds per 1 kbp DNA. Finally, the reaction mixture was allowed a final extension at
72ºC for 7 minutes and cooled to 4ºC.
Confirmation reactions contained approximately 1.0 µL DNA template or 1 µL
cultured cells, 2 µL 10x PCR Buffer (Takara Bio Incorporated) with Mg2+ , 1.6 µL dNTP
(Takara Bio Incorporated), 0.1 µL rTaq polymerase (Takara Bio Incorporated), and 0.5
µL reaction specific primers (Integrated DNA Technologies, made to 20 µL volume with
sterile autoclaved ddH2O. To begin, the DNA was denatured at 94ºC for 60 seconds.
Next, the reaction mixture was put through 35 cycles of amplification. In the
amplification process, the DNA was denatured again at 94ºC for 60 seconds, primers
were annealed at primer specific temperatures for 30 seconds, and the primers were
extended at 72ºC for 30 seconds per 1kbp DNA. At the end of these cycles, the reaction
mixture was finally extended for 7 minutes at 72ºC and subsequently cooled to 4ºC. The
DNA resulting from PCR reactions was either used immediately or stored at -20oC for
future use.
AGAROSE GEL ELECTROPHORESIS
PCR amplification and confirmation products as well as DNA fragments
generated via endonuclease restriction digestions were all visualized by agarose gel
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electrophoresis. DNA samples were mixed with 2 µL loading dye and run on 0.8% or
1.0% ethidium bromide incorporated agarose gels depending on the size of the
fragment of interest. Gels were run at 90 volts with a BioRad 3000Xi (Bio-Rad
Laboratories, Incorporated) in a Mini-Sub Cell GT (Bio-Rad Laboratories, Incorporated)
for 20 minutes. The separated DNA fragments were compared to 1KbPlus DNA Ladder
(Invitrogen Corporation) to confirm approximate size. Bands within the gels were
photographed inside a BioRad Universal Hood (Bio-Rad Laboratories, Incorporated)
equipped with a CFW-1312M grayscale digital camera and viewed with The Discovery
Series QualityOne 1-D Analysis Software version 4.6.1 (Bio-Rad Laboratories,
Incorporated).
AMPLIFIED DNA PURIFICATION
DNA fragments generated from PCR or from digestion reactions were purified
using the PureLinkTM PCR Purification Kit (Invitrogen Corporation). Binding Buffer B3
(Invitrogen Corporation) at a volume of 400 µL was added to the DNA sample and
pipetted into a PureLinkTM PCR Spin Column (Invitrogen Corporation) snapped into a
collection tube. The column in the collection tube was spun at 16,100 x g for 1 minute
and the flow through was discarded.
The column was washed by adding 650 µL Wash Buffer (Invitrogen Corporation)
to column and spun at 16,100 x g for 1 minute. The flow through was discarded and
centrifugation continued for 3 additional minutes to remove excess buffer.
The column was placed into a PureLinkTM Elution Tube (Invitrogen Corporation)
and DNA was incubated with 32 µL of sterile autoclaved ddH2O for 2 minutes. The DNA
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was eluted by spinning column at 16,100 x g for 2 minutes. The purified DNA was used
immediately or stored at -20oC for future use.
E. COLI CELL TRANSFORMATIONS
Aliquots of 50 µL DH5α competent E. coli cells (Invitrogen Corporation) were
incubated with 3 µL of ligation product DNA on ice for 35 minutes. Cells were heatshocked in a 42ºC waterbath for 45 seconds then immediately incubated on ice for 2
minutes.
To the tube, 180 µL of LB broth was added to the transformed cells and
incubated at 37ºC for 1 hour in a Forma Orbital Shaker incubator (Thermo Electron
Corperation). The cells were removed from the incubator and 100 µL to 180 µL of cells
were plated on LB plates containing the appropriate antibiotics. When needed, 4 µL

Isopropyl β-D-1-thiogalactopyranoside ,IPTG, (Applied Biosystems, Foster City, CA)
and 40 µL X-gal (Invitrogen Corporation) was also added for blue versus white
screening.
The plates were incubated at 37ºC overnight and observed for growth.
Transformation colonies were inoculated into 500 µL of LB broth containing the
appropriate antibiotic and incubated for 4 hours in a shaking incubator. Confirmed
transformant cultures were then brought up to 5 mL cultures with the addition of LB
broth containing the appropriate antibiotic and returned to the incubator for overnight
growth in preparation for plasmid recovery.
PLASMID RECOVERY
Plasmid mini preps were performed on 5 mL overnight E. coli cultures using the
Qiagen QIAprep Miniprep Kit (Valencia, Ca). Overnight cultures of 5 mL were pelleted
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at 3711 x g for 15 minutes in a Sorvall Legend RT tabletop centrifuge (Kendro
Laboratory Products, Newtown, CT).
The supernatant was discarded and the pellet was re-suspended by pipetting in
250 µL of chilled Buffer P1 with LyseBlue (Qiagen Incorporated) and added to a
microcentrifuge tube. Buffer P2 (Qiagen Incorporated) was added to the tube at a
volume of 250 µL and mixed by inversion until consistent blue color was reached. A 300
µL volume of Buffer P3 (Qiagen Incorporated) was added and mixed in immediately by
inversion. The resulting solution was centrifuged at 16,100 x g for 10 minutes. The
supernatant was removed to a QIAprep spin column (Qiagen Incorporated) and
centrifuged at 16,100 x g for 1 minute.
The flow through was discarded and the column was washed with 0.5 mL of
Buffer PB (Qiagen Incorporated). The buffer was removed via centrifugation and the
flow through discarded. The column was washed again with 0.75 mL Buffer PE (Qiagen
Incorporated). The column was spun for an additional 1 minute to remove excess buffer
then placed into a clean micro-centrifuge tube.
The DNA was eluted after the column was incubated for 1 minute with 30 µL
sterile autoclaved ddH2O by centrifugation at 16,100 x g for 1 minute. A second elution
was collected by incubating the column with 20 µL sterile autoclaved ddH2O for 1
minute and centrifuging again for 1 minute at 16,100 x g. The unused portion of plasmid
DNA was stored at -20oC for future use.
PLASMID CONSTRUCTION
DNA from strain 5A4 Borrelia burgdorferi was PCR amplified using the primers
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cp32-3F1Nco1 and cp32R2 to produce a DNA fragment that represents the putative
maintenance region of cp32-3. This 8kbp DNA fragment compared to the DNA ladder
after gel electrophoresis to confirm size and then purified. The fragment was then
digested with NcoI and purified again.
pNCO1T plasmid DNA was also digested with NcoI then purified. The digested
cp32-3 fragment was then ligated into pNCO1T to produce pNCO1Tcp32-3. The
fragment was transformed into E. coli and grown on LB-amp plates incorporated with
IPTG and X-gal. The white colonies were selected for growth in LB-amp broth. Plasmid
construction was confirmed via PCR using the concp32F and concp32R primers and
confirmed transformants were allowed to grow overnight before plasmid DNA was
recovered.
The resulting DNA was PCR amplified using cp32-3F1Nco1 and cp32-3R1Nco1
to produce the cp32-3plus fragment. The DNA resulting from the amplification was
again compared to the DNA ladder to confirm appropriate fragment size. The DNA was
then purified and digested with NcoI. The DNA fragment was then purified once more.
The plasmid DNA from pBSVGE22 was PCR amplified with Gen32F and
Gen32R primers to produce pG22. The plasmid fragment size was confirmed via gel
electrophoresis and subsequently purified. The fragment was digested with NcoI. The
ends of the fragments were dephosphorylated and the DNA fragment was purified once
more.
The cp32-3plus fragment was then ligated into the pG22 plasmid. The ligation
product, pG22cp32-3plus was transformed into E. coli and grown on LB-gent plates.
Transformants were confirmed via PCR using concp32F and concp32R and GenF and
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GenR primers. Confirmed transformants were allowed to grow overnight in LB-gent
broth. Plasmid DNA was consequently extracted for use in electroporation procedures.
BORRELIAL ELECTROPORATION
Borrelia burgdorferi strain A13 was resurrected from frozen stock into 2 mL BSKH complete media (Sigma-Aldrich Corporation) supplemented with 6% rabbit serum
(Sigma-Aldrich Corporation) and incubated inside a Forma Series II water jacketed CO2
Incubator (Thermo Electron Corporation) at 33oC and 5% CO2. Once the culture was
grown to an approximate density of 100 spirochetes per field of view, the cells were
transferred into 50 mL of media and allowed to return to 100 spirochetes per field of
view before collection.
To collect the cells, the culture was split into two 25 mL aliquots. The aliquots
were pelleted at 3711 x g for 22 minutes in a Sorvall Legend RT tabletop centrifuge.
The cells were rinsed with a total of 15 mL EPS and combined into one tube. The tube
was spun at 3711 x g for 22 minutes. Again the cells were rinsed using 5 mL EPS and
transferred into 20 mL falcon tube. The cells were spun once more at 3711 x g for 22
minutes.
After the final rinse, the cells were resuspended in 50 µL EPS. The suspension of
cells was then added to the pG22cp32-3plus DNA to be inserted into the cells and
incubated on ice for 1 minute. The chilled suspension was transferred to a pre-chilled
0.1 cm GenePulserTM electroporation cuvette (Bio-Rad Laboratories, Incorporated) for
transformation. The cuvette was placed inside the GenePulser XcellTM (Bio-Rad
Laboratories, Incorporated) set to 1.25 kV, 25 µF, 200 e for a constant time of 4-6 ms
for use. Immediately after electroporation, 1 mL of prewarmed (37oC) media was added
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to the cuvette. Working quickly, the contents of the cuvette was transferred into 35 mL
of media and incubated for 24 hours at 34oC.
After overnight incubation at 34oC, the media was supplemented with gentamycin
to a final concentration of 50 µg/mL. The culture was then aliquoted into PCR tubes at a
volume of 220 µL/tube to produce cultures with single clones. One week later the
cultures were monitored for positive transformants. All steps in the transformation
process were performed in a class II biosafety cabinet.
TRANSFORMANT IDENTIFICATION
Between 7 and 12 days after a transformation procedure, monitoring for positive
transformants began. As Borrelia grows, the bacteria lower the pH of the culture media,
changing it from a red-orange to a yellow-orange color. The color change is used as an
indicator of growth and is produced by the phenol-red dye present in the media. Phenol
red is a dye used to indicate the change in pH from 8.4 to 6.6, as the pH gradually
decreases the dye will change color from red to yellow.
All cultures were viewed under a Zeiss Axiostar plus microscope to visualize
growth. All positive cultures were confirmed via confirmation PCR using primers specific
to DNA inserted into transformed cells. All true positive cultures were transferred to 1
mL new media for further growth and use.
SELECTION PRESSURE INCREASE
In order to increase selection pressure, 1 mL cultures of positive transformants
were subjected to increasing concentrations of gentamycin. The media was originally
increased from 50 µg/mL of gentamycin to 100 µg/mL and then again increased to 150
µg/mL eight hours later.
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After twelve hours of growth, the culture was aliquoted out in 50 µL volumes into
media supplemented with varying concentrations of gentamycin ranging from 300
µg/mL to 1400 µg/mL in 100 µg increments. The new 1 mL cultures were allowed to
grow over several generations. Transformants grown in 300 µg/mL, 500 µg/mL, 700
µg/mL, and 900 µg/mL had 50 µL of culture transferred into new media supplemented
with the same concentration of gentamycin.
As marked drop-off in growth was noted at 700 µg/mL of gentamycin, the 500
µg/mL culture was recultured at 550 µg/mL and allowed twelve generations of growth.
At that time, 50 µL of the culture was removed to 1 mL new media with the same
concentration of gentamycin and allowed to grow for three more days. Following this
period of growth, 50 µL of culture was transferred into two tubes of 950 µL culture
media supplemented with 750 µg/mL or 950 µg/mL of gentamycin.
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RESULTS
SELECTION OF MAINTENANCE REGION
A previous study by Eggars and colleagues indicates that the PF57, PF50, PF32,
and PF49 genes serve as the putative maintenance region of the cp32 plasmids in the
B. burgdorferi strain 297 (2002). As the regions surrounding this area are extremely
similar between cp32 plasmids, a longer segment of DNA was amplified to ensure
amplification of only the single cp32-3 plasmid. It is by this reasoning that the 3 kbp
required region was amplified along with 5.5 kbp of DNA flanking the region (Figure 12).
The PCR amplification with the primers cp32-3F1NcoI and cp32R2 (Table 4)
produced the 8430 bp region of DNA used in the construction of plasmids in latter
experiments. After amplification, the DNA fragment size was confirmed via agarose gel
electrophoresis (Figure 13). After digestion with NcoI, the restriction site introduced with
both primers, the DNA fragment size was again confirmed using agarose gel
electrophoresis.
CREATION OF pNCO1Tcp32-3
The pNCO1T vector, which is used extensively in our laboratory, can replicate in
E. coli but does not have the necessary genes to do so in B. burgdorferi (Dowie et al.,
2004, Xu et al., 2007a, 2007b). The 8.4 kbp fragment of DNA amplified from cp32-3 was
inserted into the vector pNCO1T at the NcoI restriction site, disrupting the lacZ gene
(Figures 14,15). The resulting pNCO1Tcp32-3 plasmid was used to transform E. coli
cells that were plated onto LB-amp plates supplemented with IPTG and X-gal. Potential
successful transformants grew white colonies, as opposed to non-transformed blue
colonies (Figure 16), greatly simplifying the selection process.
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cp32-3 PUTATIVE MAINTENANCE REGION

cp32-3
30223 bp

Figure 12: cp32-3 Putative Maintenance Region. The 8.4 kb region of DNA
representing the putative maintenance region from the cp32-3 plasmid was
amplified using cp32-3F1NcoI/cp32R2 primers. The resulting fragment was used
in the construction of future plasmids.
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cp32-3 AMPLIFIED FRAGMENT

Figure 13: cp32-3 Amplified Fragment. The DNA fragment representing the
putative maintenance region of ccp32 plasmids was amplified from cp32-3 and
visualized by gel electrophoresis to confirm appropriate size. The resulting 8430
bp fragment was used in the construction of future plasmids.
Lane1:1kbp DNA Ladder
Lane2: B. burgdorferi 5A4 cp32-3 fragment (cp32-3F1NcoI/cp3R1NcoI)
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pNCO1T VECTOR COMPOSITION

pNCO1T
2955 bp

Figure 14: pNCO1T Vector Composition. The pNCO1T plasmid was cut at the
NcoI site to prepare the plasmid for the insertion of the cp32-3 fragment of DNA
that represents the punitive maintenance region of cp32-3.

pNCO1Tcp32-3 VECTOR COMPOSITION

pNCO1Tcp32-3
11385 bp

Figure 15: pNCO1Tcp32-3 Vector Composition. The pNCO1Tcp32-3 plasmid is
the result of cp32-3 fragment insertion into the NcoI site of the pNCO1T plasmid.
After the plasmid was introduced into competent E. coli cells for amplification, the
extracted plasmid was tested via confirmation PCR with concp32F and concp32R
primers to confirm the presence of the inserted cp32-3 fragment.
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BLUE VERSUS WHITE TRANSFORMANT SCREENING

Figure 16: Blue Versus White Transformant Screening. E. coli colonies
transformed with the pNCO1Tcp32-3 were grown on a LB plate supplemented with
ampicillin, IPTG, and X-gal. Blue clones are the product of an unsuccessful
transformation as they indicate an intact lacZ. The white colonies were chosen for
further testing to confirm presence of correctly constructed pNCO1Tcp32-3
plasmid.
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Although the colony color difference suggests successful transformants,
confirmation PCR was performed to ensure the presence of the inserted cp32-3
fragment. The plasmid was extracted and fragment presence was confirmed using the
confirmation primers concp32F and concp32R (Table 4). The procedure successfully
amplified the approximately 500 bp region of DNA located toward the end of the PF161
gene extending toward PF57. The amplified fragment was run through an agarose gel
and then compared in size to a DNA ladder. The size of the fragment was also
compared to the position of a positive control confirmation PCR of original cp32-3
fragment DNA.
Next, a confirmation digestion reaction was performed by digesting the plasmid
with NcoI. The two fragments were visualized by agarose gel electrophoresis to confirm
successful plasmid construction. The two fragments, the original linear pNCO1T and the
cp32-3 fragment, were compared to the DNA ladder and correctly located at
approximately 3 kbp and 8.4 kbp respectively (Figure 17).
CREATION OF pG22
The vector pNCO1T can replicate in E. coli, but not in B. burgdorferi; however,
the insertion of the putative maintenance region of cp32-3 may make the vector
reproducible in spirochetes.

The use of the pNCO1T vector is further complicated

because it does not have a selection marker that is available for use in the borrelial
system. The vector pBSVGE22 contains a selectable gentamycin acetyltransferase
gene that is constantly expressed under a borrelial FlaB promoter (Figure 18) (Stewart
et al., 2001). It also contains a copy of the B. burgdorferi gene bbe22 that is necessary
to restore infectivity to the highly transformable borrelial strain 13A, which has been
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pNCO1Tcp32-3 DIGESTION CONFIRMATION

Figure 17: pNCO1Tcp32-3 Digestion Confirmation. The plasmid DNA extracted from E.
coli after transformation was confirmed by digestion the plasmid with NcoI. The
resulting fragments at 3 kbp and 8.4 kbp correspond to the original portion of pNcoIT
and the cp32-3 fragment, respectively.
Lane 1: 1 kbp DNA Ladder
Lane 2: pNcoITcp32-3 DNA (NcoI-)
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repeatedly used in our laboratory (Xu et al., 2007a; 2007b). pBSVGE22 also contains
the necessary elements to allow for successful replication and maintenance in E. coli
cells.
As these necessary components only comprise half of the 6409 bp plasmid, the
vector was reduced in size as to aid in transformation efficiency. The plasmid DNA was
amplified via PCR with Gen32F and Gen32R primers (Table 4) to shorten the plasmid
by 3625 bp. The shortened plasmid was run through an agarose gel and compared to a
DNA ladder (Figure 20). The fragment was positioned appropriately for it 2784 bp size.
This 2784 bp fragment, which retained the origin of replication site, copy of bbe22, and
the gentamycin acetyltransferase cassette, was designated pG22 when circularized
(Figure 19).
CREATION OF pG22cp32-3plus
The pG22 plasmid, in linear form, was digested with NcoI to form cohesive ends
compatible with the NcoI digested 8.4 kbp cp32-3 fragment amplified from
pNCO1Tcp32-3. A ligation procedure was used to fuse the two fragments together to
form a plasmid of 11.2 kbp in length designated pG22cp32-3plus (Figure 21). The
following analyses were conducted to confirm pG22cp32-3plus was constructed as
designed after replication and extraction from transformed E. coli cells.
First, the confirmation PCR was run using primers amplifying the gentamycin
acetyltransferase gene, GenF and GenR (Table 4). The resulting DNA fragment was
compared in size to the DNA ladder as well as the location of a positive control obtained
using the same primers with pBSVGE22 DNA.
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pBSVGE22 VECTOR COMPOSITION

pBSVGE22
6409 bp

Figure 18: pBSVGE22 Vector Composition. The pBSVGE22 plasmid, at 6409 bp,
was reduced in size to aid in transformation efficiency. The plasmid was reduced
by amplifying a 2784 bp portion of the plasmid with the primers Gen32F and
Gen32R.
pG22 VECTOR COMPOSITION

pG22
2784 bp

Figure 19: pG22 Vector Composition. pG22 is the 2784 bp product of pBSVGE22
amplification with Gen32F and Gen32R primers. As the amplification process
introduced NcoI sites at the ends of the fragment, pG22 is ready for the insertion of
the cp32-3plus DNA fragment.
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pBSVGE22 PLASMID REDUCTION

Figure 20: pBSVGE22 Plasmid Reduction. The pBSVGE22 plasmid was amplified
with Gen32F and Gen32R primers to shorten the plasmid while retaining the
plasmids necessary function. The resulting plasmid, pG22, is 2784 bp in length
and appears as a single band on an agarose gel.
Lane 1: 1kbp DNA Ladder
Lane 2: pBSVGE22 (Gen32F/Gen32R)
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pG22cp32-3plus PLASMID COMPOSITION

pG22cp32-3plus
11214 bp

Figure 21: pG22cp32-3plus Plasmid Composition. The pG22cp32-3plus plasmid is
the result of ligating the pG22 plasmid with the cp32-3plus fragment obtained from
pNCO1Tcp32-3. The 11,214 bp pG22cp32-3plus plasmid will be introduced into
Borrelia in order to push out the native cp32-3 plasmid.
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As a second confirmation step, a second confirmation PCR was performed with
confirmation primers to cp32 as described before. Similarly, the resulting DNA fragment
was viewed after agarose gel electrophoresis. The fragment was compared to the DNA
ladder as well as the positive control PCR fragment obtained from original cp32-3
fragment DNA.
Based on these analyses, the plasmid pG22cp32-3plus contained all necessary
components to replicate in both E. coli and B. burgdorferi. In addition, the plasmid also
contained a selectable marker that can be used in both genera of bacteria as well as the
cp32-3 DNA fragment of interest. With all these components present, the plasmid is
ready for transformation into Borrelia.
CREATION OF BORRELIA BURGDORFERI TRANSFORMANTS
The pG22cp32-3plus was introduced into B. burgdorferi strain 13A by
electroporation. This particular borrelial clone is highly transformable due to the lack of
lp25 and lp56, the two plasmids that may carry restriction enzymes (Lawrenz et al.,
2002). The plasmid lp25, not lp56, is required for mammalian infection as it carries
bbe22, a gene that codes for a nicotinamidase essential for survival of B. burgdorferi in
the mammalian environment (Purser et al., 2003). The copy of the bbe22 gene present
on the pG22cp32-3plus plasmid will restore the bacteria to its naturally infectious state.
Once pG22cp32-3plus was introduced, transformed bacteria were grown under
gentamycin selection pressure at 50 mg/µL. The antibiotic added to the media
eliminated spirochetes that had not received pG22cp32-3plus. The transformed bacteria
were screened for growth using the color change in BSK-H media. Bacterial growth
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lowers the media pH changing the color from red-orange to yellow-orange (Figure 22).
The tubes containing yellow-orange media were selected for confirmation.
The growing colonies were tested to confirm the presence of the gentamycin
acetyltransferase cassette. The confirmation PCR procedure using GenF and GenR
primers (Table 4) to rule out false positive transformants due to spontaneous mutation
to a gentamycin resistant phenotype (Figure 23). All transformants that tested positive
for the cassette are true transformants that had acquired pG22cp32-3plus.
cp32-3 MAINTAINED IN PRESENCE OF pG22cp32-3plus
All transformants that acquired the pG22cp32-3plus plasmid were tested by PCR
to determine if the native cp32-3 plasmid was present. The confirmation PCR
procedure utilized the BSS41F and BSS41R primers (Table 4). In all cases, cp32-3 was
present (Figure 24).
To afford the bacteria enough time for the vector pG22cp32-3plus to displace the
cp32-3 plasmid, the cultures were maintained in fresh media supplemented with 50
mg/µL of gentamycin for an additional two weeks. After this period of growth, the
colonies were serially diluted into 96-well plates to produce single clones.
The 14 clones were again visually screened for growth by observing media color
change. The growing spirochetes were again tested for the presence of the gentamycin
acetyltransferase cassette using confirmation PCR using the GenF and GenR primers
(Table 4). Confirmation PCR was also employed to screen the transformants for the
presence of the cp32-3 plasmid as described above. While all of the 14 clones still
possessed the pG22cp32-3plus plasmid, the bacteria also maintained the cp32-3
plasmid.
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MEDIA COLOR CHANGE INDICATES GROWTH

Figure 22: Media Color Change Indicates Growth. Spirochetal growth is indicated
by a color change in the BSK-H media when the pH is lowered. The phenol red
indicator dye changes from red-orange color (shown at right) indicating a pH of
approximately 7.0 to yellow-orange color (shown at left) indicating a pH of
approximately 6.0.
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PCR SCREENING FOR pG22cp32-3plus TRANSFORMANTS

Figure 23: PCR Screening For pG22cp32-3plus Transformants. Borrelial cells
transformed with pG22cp32-3plus must be tested to confirm the presence of the
gentamycin acetyltransferase cassette to ensure true transformants. The cassette
presence was confirmed via PCR with GenF and GenR primers. False positive
transformants due to spontaneous mutation were ruled out and excluded when the
band of DNA representing the 519 bp GenF/GenR fragment did not appear on the
agarose gel (lanes 2-6 and 9).
Lane 1: 1kbp DNA Ladder
Lanes 2-13: B. burgdorferi A13 pG22cp32-3plus (GenF/GenR)
Lane 14: sterile autoclaved ddH2O (GenF/GenR)
Lane 15: pG22cp32-3plus (GenF/GenR)

52

PCR SCREENING FOR cp32-3 PLASMIDS

Figure 24: PCR Screening for cp32-3 Plasmids. Single clones of Borrelia
transformants with pG22cp32-3plus grown in 50 µg/mL of gentamycin. The
cultures were tested for the presence of the native cp32-3 plasmid. In all cases the
bacteria had eliminated the plasmid.
Lane 1 & 10: 1kbp DNA Ladder
Lanes 2-9 & 11-16: B. burgdorferi A13 pG22cp32-3plus (BBS41F/BBS41R)
Lane 17: B. burgdorferi 5A4 (BBS41F/BBS41R)
Lane 18: sterile autoclaved ddH2O (BBS41F/BBS41R)
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INCREASED SELECTION PRESSURE FORCES cp32-3 EXCLUSION
In an attempt to force the plasmid to selectively exclude the cp32-3 plasmid, the
transformants were subjected to increased selection pressure in the form of varying and
increasing gentamycin concentrations of 300 mg/µL to 1400 mg/µL. With this additional
pressure, cultures were monitored for growth. Cultures grown at 500 mg/mL were
allowed to incubate for four days in media containing 550 mg/mL of gentamycin.
At the conclusion of this growth period the culture was divided and the
gentamycin concentration was increased to 750 mg/mL and 950 mg/mL. The culture
was allowed to grow to 100 spirochetes per field of view in media supplemented with 50
mg/mL of gentamycin. The cultures were serially diluted into 96 well plates to select
single clones. Single clones were selected visually using the color change in the media
produced by growing bacteria.
In the same manor as before, the growing transformants were tested to confirm
the presence of the introduced plasmid (Figure 25). After the pG22cp32-3plus plasmid
presence was confirmed, the transformants were tested for the presence of the cp32-3
plasmid. In all cases the confirmation PCR performed with BBS41F and BBS41R
primers (Table 4) showed the cp32-3 had indeed been lost in all of 17 clones examined
(Figure 26). As an additional precautionary measure, the transformants were subjected
to yet another round confirmation PCRs. The PCRs were also performed with primers
specific to cp32-4, cp32-6, cp32-7, cp32-9 plasmids. Results confirmed the presence of
all cp32 plasmids, except for cp32-3 (Figure 27).

54

PCR CONFIRMATION OF pG22cp32-3plus PLASMID PRESENCE

Figure 25: PCR Confirmation of pG22cp32-3plus Presence. Single clones of
borrelial pG22cp32-3plus transformants grown in high concentrations of
gentamycin were tested via PCR for the presence of the gentamycin
actyltransferase cassette using GenF and GenR primers.
Lane 1: 1kbp DNA Ladder
Lanes 2: B. burgdorferi A13 pG22cp32-3plus (GenF/GenR)
Lane 3: sterile autoclaved ddH2O (GenF/GenR)
Lane 4: pG22cp32-3plus (GenF/GenR)
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PCR SCREENING FOR cp32-3 PLASMIDS
AFTER INCREASED ANTIBIOTIC SELECTION PRESSURE

Figure 26: PCR Screening for cp32-3 Plasmids After Increased Antibiotic
Selection Pressure. Single clones of borrelial pG22cp32-3plus transformants
grown in high concentrations of gentamycin were tested for the presence of the
cp32-3 plasmid. In all cases the bacteria had eliminated the plasmid.
Lane 1: 1 kbp DNA Ladder
Lanes 2-6: B. burgdorferi A13 pGE22cp32-3plus (BBS41F/BBS41R)
Lane 7: B. burgdorferi 5A4 (BBS41F/BBS41R)
Lane 8: sterile autoclaved ddH2O (BBS41F/BBS41R)

56

PCR SCREENING FOR cp32 PLASMIDS
AFTER INCREASED ANTIBIOTIC SELECTION PRESSURE

Figure 27: PCR Screening for cp32 Plasmids After Increased Antibiotic Selection
Pressure. Single clones of borrelial pG22cp32-3plus transformants grown in high
concentrations of gentamycin were tested for the presence of the cp32-3 plasmid.
In all cases the bacteria had retained cp32-4,cp32-6, cp32-7, and cp32-9
plasmids.
Lanes 1-17: B. burgdorferi A13 pG22cp32-3plus
Lane 18: B. burgdorferi 5A4
Lane 19: sterile autoclaved ddH2O
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DISCUSSION
Lyme disease has been the most commonly reported arthropod disease in the
United States for the last 23 years (Centers for Disease Control and Prevention, 1985).
Since reporting began in 1980, the number of disease cases has dramatically
increased. In 2005 there were 23,305 cases reported in 45 different states making the
incidence of Lyme disease in the United States 7.9 cases per 100,000 (Centers for
Disease Control and Prevention, 2007).
The disease produces a wide range of symptoms that can debilitate infected
persons overtime, especially if the infection is allowed to progress. The onset of the
infection produces flu-like symptoms usually accompanied by an erythema migrans rash
(Steere et al., 1983; Centers for Disease Control and Prevention, 1997). When left
untreated, the disease produces more serious symptoms including: joint pain, fatigue,
aching neck, numbness of extremities, facial palsy, headaches, and arthritis.

The

bacterial infection can also produce detrimental effects to the heart and central nervous
system (Steere, 2001; Aguero-Rosenfeld et al., 2005). The increased number of cases,
as well as the severity of disease symptoms, validates the need to study Lyme
disease’s causative agent, Borrelia burgdorferi.
Casjens et al (2000) completed the genomic work by Fraser et al. (1997) to produce
the full compilation of the Borrelia genome. The bacteria have an unusual segmented
genome comprised of a single linear chromosome complemented with up to 21
extrachromosomal plasmids.

As the chromosome is 910 kbp in length, the

extrachromosomal DNA contains 610,694 bp and makes up roughly 40% of the entire
borrelial genome (Fraser et al., 1997; Casjens et al., 2000) .
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The extrachromosomal DNA or plasmids are particularly interesting as they may
encode for genes required by the bacteria; as a result the plasmids are faithfully
maintained (Purser and Norris, 2000). Four of the bacteria’s plasmids, lp28-1, lp25,
lp56, and cp26, are recognized as required and necessary. Although the bacteria can
lose lp28-1 spontaneously, the plasmid is required to be present to produce a persistent
infection because of the vlsE region that gives the bacteria antigenic variation to a
surface exposed protein (Purser and Norris, 2000; Labandeira-Rey and Skare, 2001).
The lp25 plasmid is required for borrelial survival in the mouse due to the pncA gene
that provides a critical step in synthesizing NAD for cellular energy (Purser and Norris,
2000; Purser et al., 2003,).
Plasmid lp56 is required for cellular survival for several reasons. The plasmid
contains the genes to encode for OspA, OspB, DbpA, DbpB, and CRASP-1. The
proteins OspA and OspB aid the bacteria in tick colonization while DbpA and DbpB
facilitate the bacteria with colonization and dissemination and mediate attachment to
host tissue (Guo et al., 1995; Fischer et al., 2003; Ojaimi et al., 2003). The CRASP-1
protein assists Borreila in avoiding complement-mediated killing (Kraiczy et al., 2004).
The circular plasmid cp26 has been shown to be essential to B. burgdorferi bacterial
viability (Byram et al., 2004). The cp26 plasmids encodes for ospC and resT genes
which produce proteins that help the spirochete adhere to tissue and resolve circular
dimmers, respectively (Kobryn and Chaconas, 2002; Caimano et al., 2004).
As part of the bacteria’s extrachromosomal plasmids, a single bacterium can
maintain up to seven different cp32 plasmids (Casjens et al., 1997, Casjens et al.,
2000). These plasmids represent almost 20% of bacterial DNA. The nine plasmids that
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make up the cp32 family are each roughly 30 kbp in length and have 80% similarity
between them (Casjens et al., 2000). By characterizing natural isolates of the bacteria,
it was determined that the plasmids are well maintained during in vitro cultivation
(Purser and Norris, 2000).

No characterized isolate exists with all cp32 plasmids

missing from its repertoire (Purser and Norris, 2000). This information suggests that at
least some of the plasmids provide genetic information necessary for spirochetal
survival in nature (Casjens, et al. 1997; Purser and Norris, 2000).
At present, relatively little is known about the true function of the majority of the
cp32 plasmids’ genes (Casjens et al., 2000). Through research, three distinct
hypervariable regions have been identified on each cp32 plasmid. The first
hypervariable region, the putative plasmid maintenance region, contains the paralogous
gene families, PF57, PF50, PF32, and PF49 that responsible for the cp32 family’s
replication and segregation (Casjens et al., 2000; Stevenson and Akins, 2000; Eggers
et al., 2002). The second hypervariable region contains the erp locus that contain genes
for the OspE and OspF surface exposed lipoproteins used to help the bacteria evade
complement mediated killing (Stevenson et al., 1995; Kraiczy et al., 2001; Stevenson et
al., 2002; Kraiczy et al., 2004).
The final hypervariable region, the 2.9 loci contains genes that encode the
antigenic Mlp proteins that may assist in interacting with host tissues (Porcella, et al.
1996, Theisen 1996, Yang, et al. 1999). Most of the 2.9 loci also contain a bdr gene for
proteins that potentially play a role in cellular regulation (Meyer and Barbour, 1999;
Zückert et al.,1999; Roberts et al., 2000; Stevenson and Akins, 2000). Instead of a bdr

60

gene, cp32-1 and cp32-6 encode a rev gene to provide the bacteria survival advantages
in diverse environments (Gilmore and Mbow, 1998; Stevenson and Akins, 2000).
Outside of the hypervariable regions the cp32 plasmids similarity increases
dramatically to between 80-99% similar (Stevenson and Akins, 2000; Casjens et al.,
2000). Throughout the almost identical stretches of DNA, only one region of DNA has
been identified and characterized (Stevenson and Akins, 2000). This region, similar
amongst all cp32 plasmids, contains genes for the BlyA and BlyB pore-forming toxins
that are involved in the cellular release of bacteriophage particles (Guina and Oliver
1997; Eggers and Samuels, 1999; Stevenson and Akins, 2000; Eggers et al., 2001).
Other than these four regions of DNA, little is known about the genes encoded on the
cp32 plasmids, including whether the plasmids play a role in mammalian infection.
Studying the function of the cp32 plasmids by analyzing existing natural isolates
is not possible because no isolate has been discovered lacking all members of the cp32
family. Since every isolate does carry some combination of the plasmids and the
plasmids are difficult to knockout, another approach to study the plasmid family must be
developed. Consequently, we have designed a process that artificially displaces the
plasmids by utilizing the hypervariable region responsible for plasmid replication and
segregation to construct a plasmid that is incompatible with its cp32 counterpart. Once
introduced, the constructed plasmid will force the bacteria to lose its corresponding
plasmid. The transformed bacteria can be used to gain insight into Borrelia’s potential
requirement for the plasmids as well as the subsequent role they play in infectivity or
pathogenicity.
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In addition to the four genes from the replication and maintenance region, PF57,
PF50, PF32, and PF49, the constructed plasmid contains several other important
components. The borrelial BBE22 gene is present to restore the transformable 5A13
strain of B. burgdorferi back to a naturally infectious state.

A gentamycin

acetyltransferase gene under the constitutively expressed borrelial flaB promoter is also
located on the plasmid to serve as a selection marker for transformed bacteria.
After confirming proper construction, the pG22cp32-3plus plasmid was
introduced into Borrelia 5A13.

Ultimately, selection pressure in the form of high

concentrations of gentamycin forced the bacteria to eliminate cp32-3 plasmid. The
transformed bacteria were tested to confirm plasmid depletion.
Further studies should exploit the same plasmid construction process employed
by this experiment to create constructs corresponding to every cp32 family member.
Both individually and in combinations, these plasmids transformed into Borrelia will
produce a multitude of isolates for studies to ascertain if the plasmids confer any
advantage to the bacteria during the infectious process.
The borrelial transformants should be introduced into an established mammalian
model to study the potential difference in infectivity and pathogenicity. The mouse
model currently in use by the Liang lab is such a model that will allow the determination
of the difference between the transformants with different cp32 plasmid contents (Xu et
al., 2005; Xu et al., 2006).

The model requires intradermal injections of the

transformants into both wild-type and SCID mice.
To study infectivity, inoculated mice are sacrificed after 2 to 3 weeks. At the time
of sacrifice, tissues from the mice are collected and cultured. The cultures are then
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visually examined using dark-field microscopy for the presence of borrelial cells. If
spirochetal cells are present the transformant is in fact infectious.
For information regarding the transformants pathogenicity, mice, two weeks
postinoculation, are visually examined every other day for the development of arthritis.
The mice are sacrificed at one month postinoculation and tissues are collected. The
tissues are then prepared for analysis with quantitative polymerase chain reactions for
the presence of B. burgdorferi DNA. The severity of pathogenicity is accessed by the
degree of arthritis present compared to the quantity of borrelial DNA.
Ultimately, identifying plasmids that are associated with infectivity and
pathogenicity is the first step to determining the location of Borrelia’s essential genes.
The information gathered from the experiments outlined above can only provide
evidence for B. burgdorferi’s requirement for the cp32 plasmid. Since these plasmids
are extremely similar throughout their length, it is hypothesized that at least some of the
cp32 plasmids will be required by the bacteria. If in fact a cp32 plasmid is required for
infectivity, pathogenicity, or viability of the organism, the cp32 plasmids that are most
closely related, such as cp32-3 and cp32-7, might serve the same function in the
organism. In this case, the plasmids could be similar enough such that either plasmid
could produce a strain of Borrelia with the same phenotype.
The previously mentioned experiments can determine the bacteria’s requirement
for the cp32 plasmid family. To further explore what gene or genes present on the cp32
plasmids are required by B. burgdorferi, more specific experiments must be performed.
It will be through those experiments that the true reason for the plasmids presence will
be discovered and the link to infectivity, pathogenicity, or viability be revealed.
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